If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== History == Etoperidone was discovered by scientists at Angelini, who also discovered trazodone. Its development names have included ST-1191 and McN-A-2673-11. The INNTooltip International Nonproprietary Name etoperidone was proposed in 1976 and recommended in 1977. The drug was given brand names in Spain (Centren (Esteve) and Depraser (Lepori)) and Italy (Staff (Sigma Tau)) and was also given the brand names Axiomin and Etonin, but it is not entirely clear if it was actually marketed; the Pharmaceutical Manufacturing Encyclopedia provides no dates for commercial introduction. According to Micromedex's Index Nominum: International Drug Directory, etoperidone was indeed previously marketed in Spain and Italy.
== Formation of sugar-carbamino == The sugar-carbamino is formed through a C-glycosidic linkage with the amino acid side chain via various linkers. The synthesis involves introducing annulation to appropriate amino acid residues to rigidify glycopeptides, followed by Diels-Alder cycloadditions to fuse cyclic α- and β-amino acids to the sugar moiety. This also involves the preparation of fused bicyclic C-glycosyl α-amino acid 4, which is confirmed through 2D NMR experiments, particularly NOESY. The approach to conformationally constrained (annulated)-C-glycosyl α- and β-amino acids is based upon the Diels-Alder reaction of pyranose dienes with α- and β-nitro acrylic esters.
It served as a model for school systems across the nation. Dr. Iris T. Metts, the superintendent of schools at the time, formulated an ambitious plan to actually expand the magnet programs in PGCPS, as well as reassign magnet programs that weren't performing well at one location, to other schools. Due to long and highly publicized in-house issues between Metts and the board of education, Metts was replaced by Dr. Andre Hornsby at the end of her contract with PGCPS. When Hornsby arrived, he essentially reversed the decision that Metts had made, in regards to the future of the county's magnet programs, and he decided to instead eliminate most of the school system's magnet programs, most of which had been identified as under-performing for several years. Ten magnet programs were identified for elimination, which proved extremely controversial because some of the proposed eliminated programs were located at sites in which the program in question had been extremely successful, such as the Academic Center magnet program at Martin Luther King, Jr. Academic Center, which had been the highest performing middle school in the system for several years and also was a blue ribbon school. Despite the opposition by parents, in 2006 the magnet programs in PGCPS underwent an overhaul, and most of the magnets were eliminated. A few programs that were determined to be "successful" were either expanded and replicated at other locations, or consolidated and relocated to a dedicated magnet school that would serve large geographic areas of the county.
Sources: en.wikipedia.org
These 35 are known as primordial radionuclides. Well-known examples are uranium and thorium, but also included are naturally occurring long-lived radioisotopes, such as potassium-40. Each of the heavy primordial radionuclides participates in one of the four decay chains.
=== Cancer risk === Studies are mixed on whether the risk of breast cancer is increased with hormone therapy in transgender women. Two cohort studies found no increase in risk relative to cisgender men, whereas another cohort study found an almost 50-fold increase in risk such that the incidence of breast cancer was between that of cisgender men and cisgender women. There is no evidence that breast cancer risk in transgender women is greater than in cisgender women. Twenty cases of breast cancer in transgender women have been reported as of 2019. Cisgender men with gynecomastia have not been found to have an increased risk of breast cancer. It has been suggested that a 46,XY karyotype (one X chromosome and one Y chromosome) may be protective against breast cancer compared to having a 46,XX karyotype (two X chromosomes). Men with Klinefelter's syndrome (47,XXY karyotype), which causes hypoandrogenism, hyperestrogenism, and a very high incidence of gynecomastia (80%), have a dramatically (20- to 58-fold) increased risk of breast cancer compared to karyotypical men (46,XY), closer to the rate of karyotypical women (46,XX). The incidences of breast cancer in karyotypical men, men with Klinefelter's syndrome, and karyotypical women are approximately 0.1%, 3%, and 12.5%, respectively. Women with complete androgen insensitivity syndrome (46,XY karyotype) never develop male sex characteristics and have normal and complete female morphology, including breast development, yet have not been reported to develop breast cancer.
644 1787 L'intégration de quelques équations aux différences Partielles (Legendre transform) In Memoires présentés par divers Savants à la l'Académie des Sciences de l'Institut de France 1806 Nouvelle formula pour réduire en distances vraies les distances apparentes de la Lune au Soleil ou à une étoile (30–54) 1807 Analyse des triangles tracés sur la surface d'un sphéroide (130–161) Tome 10 Recherches sur diverses sortes d'intégrales défines (416–509) 1819 Méthode des moindres carrés pour trouver le milieu le plus probable entre les résultats de différentes observations (149–154), Mémoire sur l'attraction des ellipsoïdes homogènes (155–183) 1823 Recherches sur quelques objets d'Analyse indéterminée et particulièrement sur le théorème de Fermat (1–60) 1828 Mémoire sur la détermination des fonctions Y et Z que satisfont à l'équation 4(X^n-1) = (X-1)(Y^2+-nZ^2), n étant un nombre premier 4i-+1 (81–100) 1833 Réflexions sur différentes manières de démontrer la théorie des parallèles ou le théorème sur la somme des trois angles du triangle, avec 1 planche (367–412)
=== Hoechst stains === Hoechst is a bis-benzimidazole derivative compound that binds to the minor groove of DNA. Often used in fluorescence microscopy for DNA staining, Hoechst stains appear yellow when dissolved in aqueous solutions and emit blue light under UV excitation. There are two major types of Hoechst: Hoechst 33258 and Hoechst 33342. The two compounds are functionally similar, but with a little difference in structure. Hoechst 33258 contains a terminal hydroxyl group and is thus more soluble in aqueous solution, however this characteristics reduces its ability to penetrate the plasma membrane. Hoechst 33342 contains an ethyl substitution on the terminal hydroxyl group (i.e. an ethylether group) making it more hydrophobic for easier plasma membrane passage
Sources: en.wikipedia.org
=== Sports journalists === Jeremy Gaige (1951), chess archivist and journalist Paul Zimmerman (1955), football writer for Sports Illustrated known as "Dr. Z" Robert Lipsyte (1957), sports writer for The New York Times, correspondent for ABC News and host of The Eleventh Hour Chet Forte (1957), first director of Monday Night Football Steven Krasner (1975), sports journalist famous for covering the Boston Red Sox for The Providence Journal 1986–2008 Bob Klapisch (1979), sports writer for The Record and Fox Sports Gary Cohen (1981), television play-by-play announcer for the New York Mets
Wound licking is an instinctive response in humans and many other animals to cover an injury or second degree burn with saliva. Dogs, cats, small rodents, horses, and primates, including humans, all lick wounds. Saliva contains tissue factor which promotes the blood clotting mechanism. The enzyme lysozyme is found in many tissues and is known to attack the cell walls of many gram-positive bacteria, aiding in defense against infection. Tears are also beneficial to wounds due to the lysozyme enzyme. However, there are also infection risks due to bacteria in the mouth.
Alongside continued research defensive countermeasures there has been a proliferation of nuclear weapons around the world. Many nations have acquired technology required to produce nuclear weapons since the end of the Cold War. India tested its first nuclear weapon with Operation Smiling Buddha in 1974. It was followed by Pakistan's nuclear program acquiring centrifuges capable of enriching uranium in the 80's and in 1998 was able to conduct several underground tests. Today the United States, Russia, the United Kingdom, France, and China all possess nuclear weapons and have signed the Nuclear Non-Proliferation Treaty in an attempt to curb the spread of nuclear weapons. India, Pakistan, Israel and North Korea are also in possession of nuclear technology but have not signed the Nuclear Non-Proliferation Treaty. The Cold War brought with it increased research into radio technology as well as nuclear weapons. The success of Sputnik 1 lead to an increase funding for radio telescopes such as Jodrell Bank Observatory for use in tracking Sputnik and possible nuclear launches by the Soviet Union. Jodrell Bank and other observatories like it have since been used to track space probes as well as investigate quasars, pulsars, and meteoroids. Satellites such as the Vela that were originally launched to detect nuclear detonation following the Partial Nuclear Test Ban Treaty have been used since then to discover and further investigate gamma-ray bursts. A new space race began in the 2020s, largely between the United States' Artemis Program and China's Lunar Exploration Program.
== Etymology == The earliest known record of the name Belize appears in the journal of the Dominican priest Fray José Delgado, dating to 1677. Delgado recorded the names of three major rivers that he crossed while travelling north along the Caribbean coast: Rio Soyte (Sittee River), Rio Kibum Sibun River, and Rio Balis (Belize River). The waterways' names were provided to Delgado by his translator. It has been proposed that Delgado's "Balis" was actually the Mayan word belix (or beliz), meaning "muddy water", although no such Mayan word actually exists. More recently, it has been proposed that the name comes from the Mayan phrase bel Itza ("the way to Itza"). In the 1820s, the legend grew up that the toponym Belize derived from the Spanish pronunciation of the name of a Scottish buccaneer, Peter Wallace, said to have established a settlement at the mouth of the Belize River in 1638. There is no proof that buccaneers settled in this area and there is no evidence of the very existence of Wallace. Writers and historians have suggested several other possible etymologies, including postulated French and African origins.
The oil is distilled from the wood of the entire tree including stump and roots. Australian sandalwood (S. spicatum) is unique in that the white sapwood does not require removal before distilling the oil, while Indian Sandalwood (S. album) does require removal of the sapwood prior to distillation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.